United Kingdom · Report · Written statement
UIN HCWS30
Favipiravir (FAVI) – Contingent Liability
Introduced
18 May 2026
Last action
18 May 2026 · Written statement
Status
Commons
Sponsors
—
Subjects
Discovery layer
Source updated
18 May 2026
Summary
The UK Health Security Agency (UKHSA) is receiving a supply of doses of the antiviral medicine favipiravir (FAVI) from the Government of Japan to support the United Kingdom’s preparedness and response to Hantavirus.Favipiravir is not currently licensed fo...
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
18 May 2026
Written statement
The UK Health Security Agency (UKHSA) is receiving a supply of doses of the antiviral medicine favipiravir (FAVI) from the Government of Japan to support the United Kingdom’s preparedness and response to Hantavirus.Favipiravir is not currently licensed fo...
Source: Commons
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-statements/detail/2026-05-18/HCWS30
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenstatements/statements/1906268
- uk · ws-1906268 · source updated 18 May 2026